Skip To Main Content
Millie Hoe on Muck Rack

Millie Hoe

(She/Her)
London
As seen in: EIN News, BioXconomy, BioProcess International Magazine
Covers:  Biomanufacturing Biological sciences Biologics/ large molecules Health and technology Scientific advancements Science and health news
Doesn't Cover: Small molecules, oral drugs

Get in touch with Millie

Contact Millie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Millie Hoe’s Biography

Read Full Bio →

MSc (Sci) Life Sciences Reporter for BioXconomy and BioProcess Insider. Official member of the British Association of Journalists.

Covering biologics, US drug regulatory policy, bio-manufacturing, antibodies, mRNA, peptides, nucleic acids, CRISPR technology and other advanced therapies.

First Class Honours (BSc) Biomedical Sciences and Distinction in Masters of Science (MSc Sci)

Millie Hoe’s Journalist Portfolio

See all →
FDA pilot to supercharge US drug production

FDA pilot to supercharge US drug production

The PreCheck pilot program brings together seven pharma companies in an attempt to build domestic drug supply…

View article →
Roche launches additional Phase III DMD trial to win over EMA

Roche launches additional Phase III DMD trial to win over EMA

The European regulator denied the company marketing authorization last year after Elevidys failed to meet end…

View article →
Roche launches additional Phase III DMD trial to win over EMA

Roche launches additional Phase III DMD trial to win over EMA

The European regulator denied the company marketing authorization last year after Elevidys failed to meet end…

View article →
Europe widens biomanufacturing gap between EU and US

Europe widens biomanufacturing gap between EU and US

A data analytics report has found US facilities have remained static aside European growth.

View article →
Biotech companies tout benefits of AI-assisted drug development

Biotech companies tout benefits of AI-assisted drug development

Companies are pointing to areas like preclinical oncology and early Alzheimer's detection as use cases for th…

View article →
Regeneron to provide therapy for genetic hearing loss for free

Regeneron to provide therapy for genetic hearing loss for free

The AAV-delivered medicine is the first and only FDA-approved treatment of its kind but has raised ethical qu…

View article →

Articles

Earth's mightiest manufacturers: FDA pilot to supercharge US drug production Original

|
By Millie Hoe
| BioXconomy
The PreCheck pilot program brings together seven pharma companies in an attempt to build domestic drug supply chains. Millie Hoe,Reporter,BioProcess Insider The US Food and Drug Administration (FDA) has announced the launch of its PreCheck Pilot program with the goal of investing in and strengthening domestic manufacturing of pharmaceuticals.
Open in Who Shared View Duplicates (2) Issue with article?

Sarepta launches additional Phase III trial to win over EMA for DMD gene therapy

|
By Millie Hoe
| BioXconomy
The European regulator denied the company marketing authorization last year after Elevidys failed to meet endpoints. Millie Hoe,Reporter,BioProcess Insider Roche partner Sarepta Pharmaceuticals recently announced it will launch its second attempt at a Phase III clinical trial for its gene therapy, Elevidys. The adeno-associated viral (AAV) drug aims to treat the rare disorder Duchenne muscular dystrophy (DMD).
Open in Who Shared Issue with article?

Europe widens biomanufacturing gap between EU and US

|
By Millie Hoe
| BioProcess International Magazine Verified
Millie Hoe,Reporter, BioProcess International Earlier this month, data analytics and consulting firm GlobalData released a report citing an increasingly widening biomanufacturing gap between the US and the EU. The outsourcing of manufacturing of approved drugs and biosimilars has recently shifted more to European sites with the US lagging behind.
Open in Who Shared Issue with article?
See all 164 articles

Interview

See all →

What does it mean to be a journalist?

Highlighting important issues and news that may not be accessible for all, and making it available for the general public.

Who do you wish followed you?

Ben Goldacre- an excellent columnist and scientific writer that wrote bestseller 'Bad Science'

Why did you become a journalist?

I have a passion for healthcare, science and writing, and love to explore complex ideas for both a general and scientific audience.